safety
antigenicity
inactivated
influenza
virus
vaccine
child
trial
monovalent
bivalent
new
jersey
hswn
victoria
virus
vaccine
washington
c
safety
antigenicity
monovalent
bivalent
new
jersey
nj
hssn
victoria
inactivated
influenza
virus
vaccine
studied
child
aged
three
year
recruitment
family
knew
study
team
professionally
involved
close
continuing
care
likely
volunteer
study
unfamiliar
team
institution
antibody
response
systemic
reaction
occurred
often
administration
inactivated
whole
virus
vaccine
split
virus
vaccine
significant
titer
greater
equal
hemagglutination
inhibiting
antibody
nj
virus
occurred
normal
child
three
year
age
received
two
dos
vaccine
whole
split
however
insufficient
number
child
achieved
reasonable
antibody
titer
greater
equal
one
dose
vaccine
